STOCK TITAN

[Form 4] MiMedx Group, Inc Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

MiMedx Group director Tiffany Olson received an annual restricted stock grant of 28,609 shares on June 18, 2025, at a price of $6.47 per share. Following this transaction, Olson's direct ownership increased to 57,597 shares.

Key details of the grant:

  • Transaction was filed as an exempt grant under Rule 16b-3
  • Vesting occurs at the earlier of 12 months or next annual shareholder meeting
  • Grant is part of standard non-employee director compensation
  • Transaction was executed through attorney-in-fact William F. Hulse

This Form 4 filing represents routine board compensation and indicates continued alignment between director and shareholder interests through equity-based compensation.

La direttrice di MiMedx Group, Tiffany Olson, ha ricevuto una concessione annuale di azioni vincolate pari a 28.609 azioni il 18 giugno 2025, al prezzo di 6,47 $ per azione. Dopo questa operazione, la proprietà diretta di Olson è aumentata a 57.597 azioni.

Dettagli chiave della concessione:

  • L'operazione è stata registrata come concessione esente ai sensi della Regola 16b-3
  • Il consolidamento delle azioni avviene dopo 12 mesi o alla successiva assemblea annuale degli azionisti, a seconda di quale evento si verifichi prima
  • La concessione fa parte della normale retribuzione per i direttori non dipendenti
  • L'operazione è stata eseguita tramite il procuratore William F. Hulse

Questa comunicazione tramite il modulo Form 4 rappresenta una compensazione ordinaria del consiglio e indica un continuo allineamento tra gli interessi del direttore e quelli degli azionisti attraverso una remunerazione basata su azioni.

La directora de MiMedx Group, Tiffany Olson, recibió una concesión anual de acciones restringidas por 28,609 acciones el 18 de junio de 2025, a un precio de $6.47 por acción. Tras esta transacción, la propiedad directa de Olson aumentó a 57,597 acciones.

Detalles clave de la concesión:

  • La transacción fue presentada como una concesión exenta bajo la Regla 16b-3
  • La adquisición ocurre al cumplirse 12 meses o en la próxima junta anual de accionistas, lo que ocurra primero
  • La concesión forma parte de la compensación estándar para directores no empleados
  • La transacción fue ejecutada a través del apoderado William F. Hulse

Esta presentación en el Formulario 4 representa una compensación rutinaria del consejo y refleja la continua alineación entre los intereses del director y los accionistas mediante una compensación basada en acciones.

MiMedx 그룹 이사 티파니 올슨은 2025년 6월 18일에 28,609주의 연간 제한 주식을 주당 6.47달러 가격으로 부여받았습니다. 이 거래 후 올슨의 직접 소유 주식은 57,597주로 증가했습니다.

주요 부여 내용:

  • 거래는 규칙 16b-3에 따른 면제 부여로 신고됨
  • 베스팅은 12개월 경과 또는 다음 연례 주주총회 중 빠른 시점에 발생
  • 부여는 비임원 이사에 대한 표준 보상의 일부
  • 거래는 법정대리인 윌리엄 F. 헐스(William F. Hulse)를 통해 실행됨

이 Form 4 신고는 일상적인 이사회 보상을 나타내며, 주식 기반 보상을 통해 이사와 주주 간 이해관계가 계속 일치함을 보여줍니다.

La directrice du groupe MiMedx, Tiffany Olson, a reçu une attribution annuelle d’actions restreintes de 28 609 actions le 18 juin 2025, au prix de 6,47 $ par action. Suite à cette opération, la détention directe d’Olson est passée à 57 597 actions.

Détails clés de l’attribution :

  • La transaction a été déclarée comme une attribution exonérée selon la règle 16b-3
  • L’acquisition des droits intervient au plus tôt 12 mois ou lors de la prochaine assemblée annuelle des actionnaires
  • L’attribution fait partie de la rémunération standard des administrateurs non salariés
  • La transaction a été réalisée par le mandataire William F. Hulse

Ce dépôt au formulaire 4 représente une rémunération courante du conseil d’administration et indique une alignement continu entre les intérêts de l’administratrice et ceux des actionnaires via une rémunération en actions.

Die Direktorin von MiMedx Group, Tiffany Olson, erhielt am 18. Juni 2025 eine jährliche Zuteilung von 28.609 eingeschränkten Aktien zu einem Preis von 6,47 $ pro Aktie. Nach dieser Transaktion erhöhte sich Olsons direkte Beteiligung auf 57.597 Aktien.

Wichtige Details der Zuteilung:

  • Die Transaktion wurde als befreite Zuteilung gemäß Regel 16b-3 gemeldet
  • Die Vesting erfolgt entweder nach 12 Monaten oder auf der nächsten jährlichen Hauptversammlung, je nachdem, was zuerst eintritt
  • Die Zuteilung ist Teil der üblichen Vergütung für nicht angestellte Direktoren
  • Die Transaktion wurde durch den Bevollmächtigten William F. Hulse ausgeführt

Diese Form 4-Meldung stellt eine routinemäßige Vorstandsvergütung dar und zeigt die fortgesetzte Ausrichtung der Interessen von Direktor und Aktionären durch aktienbasierte Vergütung.

Positive
  • None.
Negative
  • None.

La direttrice di MiMedx Group, Tiffany Olson, ha ricevuto una concessione annuale di azioni vincolate pari a 28.609 azioni il 18 giugno 2025, al prezzo di 6,47 $ per azione. Dopo questa operazione, la proprietà diretta di Olson è aumentata a 57.597 azioni.

Dettagli chiave della concessione:

  • L'operazione è stata registrata come concessione esente ai sensi della Regola 16b-3
  • Il consolidamento delle azioni avviene dopo 12 mesi o alla successiva assemblea annuale degli azionisti, a seconda di quale evento si verifichi prima
  • La concessione fa parte della normale retribuzione per i direttori non dipendenti
  • L'operazione è stata eseguita tramite il procuratore William F. Hulse

Questa comunicazione tramite il modulo Form 4 rappresenta una compensazione ordinaria del consiglio e indica un continuo allineamento tra gli interessi del direttore e quelli degli azionisti attraverso una remunerazione basata su azioni.

La directora de MiMedx Group, Tiffany Olson, recibió una concesión anual de acciones restringidas por 28,609 acciones el 18 de junio de 2025, a un precio de $6.47 por acción. Tras esta transacción, la propiedad directa de Olson aumentó a 57,597 acciones.

Detalles clave de la concesión:

  • La transacción fue presentada como una concesión exenta bajo la Regla 16b-3
  • La adquisición ocurre al cumplirse 12 meses o en la próxima junta anual de accionistas, lo que ocurra primero
  • La concesión forma parte de la compensación estándar para directores no empleados
  • La transacción fue ejecutada a través del apoderado William F. Hulse

Esta presentación en el Formulario 4 representa una compensación rutinaria del consejo y refleja la continua alineación entre los intereses del director y los accionistas mediante una compensación basada en acciones.

MiMedx 그룹 이사 티파니 올슨은 2025년 6월 18일에 28,609주의 연간 제한 주식을 주당 6.47달러 가격으로 부여받았습니다. 이 거래 후 올슨의 직접 소유 주식은 57,597주로 증가했습니다.

주요 부여 내용:

  • 거래는 규칙 16b-3에 따른 면제 부여로 신고됨
  • 베스팅은 12개월 경과 또는 다음 연례 주주총회 중 빠른 시점에 발생
  • 부여는 비임원 이사에 대한 표준 보상의 일부
  • 거래는 법정대리인 윌리엄 F. 헐스(William F. Hulse)를 통해 실행됨

이 Form 4 신고는 일상적인 이사회 보상을 나타내며, 주식 기반 보상을 통해 이사와 주주 간 이해관계가 계속 일치함을 보여줍니다.

La directrice du groupe MiMedx, Tiffany Olson, a reçu une attribution annuelle d’actions restreintes de 28 609 actions le 18 juin 2025, au prix de 6,47 $ par action. Suite à cette opération, la détention directe d’Olson est passée à 57 597 actions.

Détails clés de l’attribution :

  • La transaction a été déclarée comme une attribution exonérée selon la règle 16b-3
  • L’acquisition des droits intervient au plus tôt 12 mois ou lors de la prochaine assemblée annuelle des actionnaires
  • L’attribution fait partie de la rémunération standard des administrateurs non salariés
  • La transaction a été réalisée par le mandataire William F. Hulse

Ce dépôt au formulaire 4 représente une rémunération courante du conseil d’administration et indique une alignement continu entre les intérêts de l’administratrice et ceux des actionnaires via une rémunération en actions.

Die Direktorin von MiMedx Group, Tiffany Olson, erhielt am 18. Juni 2025 eine jährliche Zuteilung von 28.609 eingeschränkten Aktien zu einem Preis von 6,47 $ pro Aktie. Nach dieser Transaktion erhöhte sich Olsons direkte Beteiligung auf 57.597 Aktien.

Wichtige Details der Zuteilung:

  • Die Transaktion wurde als befreite Zuteilung gemäß Regel 16b-3 gemeldet
  • Die Vesting erfolgt entweder nach 12 Monaten oder auf der nächsten jährlichen Hauptversammlung, je nachdem, was zuerst eintritt
  • Die Zuteilung ist Teil der üblichen Vergütung für nicht angestellte Direktoren
  • Die Transaktion wurde durch den Bevollmächtigten William F. Hulse ausgeführt

Diese Form 4-Meldung stellt eine routinemäßige Vorstandsvergütung dar und zeigt die fortgesetzte Ausrichtung der Interessen von Direktor und Aktionären durch aktienbasierte Vergütung.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Olson Tiffany

(Last) (First) (Middle)
1775 WEST OAK COMMONS CT NE

(Street)
MARIETTA GA 30062

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
MIMEDX GROUP, INC. [ MDXG ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/18/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 06/18/2025 A 28,609(1) A $6.47 57,597 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Represents annual restricted stock grant to non-employee directors. Grant is exempt under Rule 16b-3. The award vests upon the earlier of 12 months or the next annual meeting of shareholders
Remarks:
/s/ William F. Hulse as attorney-in-fact Tiffany Olson 06/23/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many MDXG shares did Director Tiffany Olson acquire on June 18, 2025?

Director Tiffany Olson acquired 28,609 shares of MDXG common stock on June 18, 2025, as part of an annual restricted stock grant to non-employee directors at a price of $6.47 per share.

What is the vesting period for MDXG's director stock grants in 2025?

The restricted stock grant for MDXG non-employee directors vests upon the earlier of 12 months from the grant date or the next annual meeting of shareholders, as disclosed in the Form 4 filing.

How many MDXG shares does Tiffany Olson own after the June 2025 stock grant?

Following the reported transaction, Tiffany Olson directly owns 57,597 shares of MDXG common stock, as indicated in Table I of the Form 4 filing.

Was MDXG Director Tiffany Olson's stock acquisition made under Rule 10b5-1?

No, the stock acquisition was not made under Rule 10b5-1. The Form 4 indicates this was an annual restricted stock grant to non-employee directors that is exempt under Rule 16b-3.
Mimedx Group Inc

NASDAQ:MDXG

MDXG Rankings

MDXG Latest News

MDXG Latest SEC Filings

MDXG Stock Data

877.35M
144.97M
2.72%
69.9%
2.78%
Biotechnology
Surgical & Medical Instruments & Apparatus
Link
United States
MARIETTA